INCY

Incyte (NasdaqGS: INCY) and Adagene have started first patient dosing in a Phase 1 trial combining INCA33890 with muzastotug for microsatellite stable colorectal cancer.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $1.56 billion.

Moby summary of Incyte Corporation's Q3 2026 earnings call

Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales.

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year to $1.56 billion.

Incyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

(INCY) on Thursday reported a loss of $784.On a per-share basis, the Wilmington, Delaware-based company said it had a loss of $3.